Project Grant R43FD007247

This Project Grant award from the National Human Genome Research Institute (NHGRI), under the Human Genome Research program (CFDA 93.172), provides $503,448.64 to the University of Colorado-Denver to develop new computational methods for accurately genotyping short tandem repeat (STR) variations from sequencing data. The goal is to create a publicly available resource of STR variation data stratified by ancestry to enable prioritization of candidate pathogenic STR expansions in rare disease...

This Project Grant award from the National Human Genome Research Institute (NHGRI), under the Human Genome Research program (CFDA 93.172), provides $406,500 to Directseq Biosciences, Inc. to advance high-throughput mass spectrometry-based sequencing (NGMS-SEQ) methods for direct sequencing and quantitative mapping of RNA modifications. The key objectives are to: 1) enhance NGMS-SEQ techniques to enable high-throughput direct sequencing of various tRNA samples, including physiologically...

This Project Grant award from the National Human Genome Research Institute (NHGRI), under the Human Genome Research program (CFDA 93.172), is for the development of an exhaustive de novo RNA sequencing method using next-generation mass spectrometry (NGMS-seq). The $215,088 award to Directseq Biosciences, Inc. aims to 1) further advance NGMS-seq to completely sequence all RNA species in a sample, including comprehensive identification and quantification of RNA modifications, and 2) test the...

The National Human Genome Research Institute (NHGRI), under the Human Genome Research Federal Grant Program (CFDA 93.172), awarded a $384,418 Project Grant to Xgenomes Corp. to develop a revolutionary DNA sequencing platform. The project aims to create a super-resolution single-molecule sequencing technology that can read short DNA sequence segments or "words" by measuring the kinetics of oligonucleotide probe binding. This approach is expected to significantly improve sequencing...

This Project Grant award from the National Institutes of Health's National Human Genome Research Institute provided $768,678 to Molecular Assemblies, Inc. to develop a fully enzymatic oligonucleotide synthesis cycle using engineered template-independent polymerases and a novel phosphate dNTP blocking group. The award supports the goals of the Human Genome Research program (CFDA 93.172) to accelerate genome research and its application to human health. Specifically, the awardee will engineer...

This Project Grant award from the National Human Genome Research Institute (CFDA 93.172 - Human Genome Research) provides $452,375 to The Trustees of Columbia University in the City of New York to develop a platform for rapid and efficient generation of multi-site sequence variants using template-guided gene synthesis. The project aims to advance this synthesis approach by optimizing predictive algorithms, experimental protocols, and robotic automation to produce kilobase-sized DNA constructs up...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) provides $350,000 to Electronic Biosciences, Inc., a small biotechnology company, to develop a novel technology for high-accuracy sequencing of the RNA modifications pseudouridine (Ps) and N6-methyladenosine (M6A). The project aims to merge the company's nanopore-based sequencing platform with innovative bisulfite adduct methodology...

The National Human Genome Research Institute (NHGRI) awarded a $397,599 Project Grant (CFDA 93.172 - Human Genome Research) to Xgenomes Corp., a minority-owned small business, to develop a novel epigenetic analysis platform for high-accuracy DNA methylation detection. The project aims to optimize the chemistry and validation of a single-molecule platform that measures transient binding kinetics of fluorescently-labeled probes to determine methylation status along DNA sequences. This innovative...

This Project Grant award for $415,712 from the National Human Genome Research Institute (NHGRI) under the Human Genome Research Federal Grant Program (CFDA 93.172) supports research to determine which genes should be included in public health newborn sequencing programs. The key objectives are to: Appraise and contrast the gene selection approaches and criteria used by experts conducting newborn sequencing pilot studies. This will synthesize decision frameworks, key criteria (e.g. actionability,...

The National Human Genome Research Institute (NHGRI), under the Federal Grant Program "Human Genome Research" (CFDA 93.172), awarded a $407,291 Phase I Small Business Innovation Research (SBIR) grant to Electronic Biosciences, Inc. to develop a nanopore-based protein sequencing platform. The project aims to create a high-accuracy, label-free nanopore reader capable of direct, single-molecule protein sequencing. This novel technology would enable proteome-wide profiling, biomarker...